Comparing Bacillus Calmette-Guérin (BCG) strains in convalescent COVID-19 patients.
Immunotherapy
; 15(1): 9-15, 2023 01.
Article
in English
| MEDLINE | ID: covidwho-2198204
ABSTRACT
Aim:
We previously published results of the BATTLE trial, showing that patients recently infected with SARS-CoV-2 can benefit from receiving Bacillus Calmette-Guérin (BCG) with minimal adverse effects. The study incorporated two strains of this vaccine. In this study, patient outcomes were compared based on the strain of BCG because different strains have been shown to have different immunogenicity.Methods:
BATTLE was a double-blind controlled trial of COVID-19 convalescent patients; symptom progression, injection-site lesion characteristics and adverse effects were compared between recipients of placebo, Russian BCG strain or Brazilian BCG strains.Results:
There was no statistically significant difference between the two BCG strains in terms of symptom progression, lesion-size or type.Conclusion:
The two strains have similar clinical outcomes in COVID-19 convalescent patients.
We previously published results of the BATTLE trial, showing that patients recently infected with SARS-CoV-2 virus can benefit from receiving BCG with minimal adverse effects. This article shows that the two BCG strains, Russian and Brazilian, have similar clinical outcomes in COVID-19 convalescent patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
Asia
/
Europa
Language:
English
Journal:
Immunotherapy
Journal subject:
Allergy and Immunology
/
Therapeutics
Year:
2023
Document Type:
Article
Affiliation country:
Imt-2022-0048
Similar
MEDLINE
...
LILACS
LIS